This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Ucbbiopharma Srl, Ucb Biopharma Sprl. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2022
Title: Gregory Foulkes: Innovator in IL-17 Modulation
Introduction
Gregory Foulkes, based in Abingdon, GB, is a notable inventor who has made significant contributions to the field of medicinal chemistry. With a robust portfolio of five patents, his work primarily focuses on the development of compounds that modulate human IL-17 activity, which plays a crucial role in inflammatory and autoimmune disorders.
Latest Patents
Foulkes’s latest patents include innovative compounds like the "Fused Imidazole Derivatives as IL-17 Modulators" and "Spirocyclic Indane Analogues as IL-17 Modulators." The first patent features a series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives, that serve as potent modulators of human IL-17 activity. These compounds hold promise in the treatment and prevention of various inflammatory and autoimmune disorders. Similarly, the second patent highlights spirocyclic indane derivatives of Formula (I) which also function as potent modulators of IL-17, offering benefits in managing similar health challenges.
Career Highlights
Throughout his career, Gregory has held significant positions in reputable companies such as UCB Biopharma SRL and UCB Biopharma SprL. His work in these organizations has been instrumental in advancing research and development related to the treatment of complex inflammatory diseases.
Collaborations
Collaboration is key in the research landscape, and Foulkes has worked alongside esteemed professionals such as Zhaoning Zhu and Gareth Neil Brace. Their combined expertise enhances the innovation process, driving the potential for breakthroughs in therapeutic solutions.
Conclusion
Gregory Foulkes stands out as a dedicated inventor in the domain of IL-17 modulation. With a strong patent portfolio reflecting his innovative spirit and collaborative efforts, he continues to significantly impact the landscape of treatments for inflammatory and autoimmune disorders. His work not only exemplifies the spirit of innovation but also ignites hope for patients affected by these challenging conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile